David A. Siegel Puma Biotechnology, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 255,300 shares of PBYI stock, worth $791,430. This represents 0.0% of its overall portfolio holdings.
Number of Shares
255,300
Previous 284,800
10.36%
Holding current value
$791,430
Previous $1.23 Million
9.73%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding PBYI
# of Institutions
99Shares Held
29.5MCall Options Held
842KPut Options Held
32.2K-
Vanguard Group Inc Valley Forge, PA3.49MShares$10.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.17MShares$9.82 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.82MShares$8.73 Million0.78% of portfolio
-
Acadian Asset Management LLC Boston, MA1.96MShares$6.07 Million0.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.73MShares$5.36 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $141M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...